Showing results (81-90 of 421) with videos related to
Sort By:
Pageof 43
Urology|April 21, 2007
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American menAlayne D Markland, Ian M Thompson, Donna P Ankerst, et al.The Journal of Urology|November 13, 2004
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.The Journal of Urology|June 16, 2009
Chemoprevention of prostate cancerIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.Journal of Clinical Epidemiology|February 17, 2015
A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validationSonja Grill, Mahdi Fallah, Robin J Leach, et al.Current Urology Reports|April 25, 2006
Prostate cancer detection strategiesTimothy C Brand, Javier Hernandez, Edith D Canby-Hagino, et al.The American Journal of Medicine|August 9, 2005
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancerSteven B Zeliadt, Ruth D Etzioni, David F Penson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.Urology|May 6, 2008
Does the level of prostate cancer risk affect cancer prevention with finasteride?Ian M Thompson, Catherine M Tangen, Howard L Parnes, et al.Controlled Clinical Trials|December 31, 2002
Biomarker-based methods for determining noncompliance in a prevention trialDonna K Pauler, Kathryn B Gower, Phyllis J Goodman, et al.BMC Urology|October 3, 2015
A case control study of sarcosine as an early prostate cancer detection biomarkerDonna P Ankerst, Michael Liss, David Zapata, et al.Pageof 43